BIOMAT Database Logo BIOMAT Database Logo

Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies. 2017

K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
Eli Lilly Biotechnology Center, 10300 Campus Point Drive, San Diego, California, 92121.

The use of bispecific antibodies (BsAbs) to treat human diseases is on the rise. Increasingly complex and powerful therapeutic mechanisms made possible by BsAbs are spurring innovation of novel BsAb formats and methods for their production. The long-lived in vivo pharmacokinetics, optimal biophysical properties and potential effector functions of natural IgG monoclonal (and monospecific) antibodies has resulted in a push to generate fully IgG BsAb formats with the same quaternary structure as monoclonal IgGs. The production of fully IgG BsAbs is challenging because of the highly heterogeneous pairing of heavy chains (HCs) and light chains (LCs) when produced in mammalian cells with two IgG HCs and two LCs. A solution to the HC heterodimerization aspect of IgG BsAb production was first discovered two decades ago; however, addressing the LC mispairing issue has remained intractable until recently. Here, we use computational and rational engineering to develop novel designs to the HC/LC pairing issue, and particularly for κ LCs. Crystal structures of these designs highlight the interactions that provide HC/LC specificity. We produce and characterize multiple fully IgG BsAbs using these novel designs. We demonstrate the importance of specificity engineering in both the variable and constant domains to achieve robust HC/LC specificity within all the BsAbs. These solutions facilitate the production of fully IgG BsAbs for clinical use.

UI MeSH Term Description Entries
D007143 Immunoglobulin Heavy Chains The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa. Immunoglobulins, Heavy-Chain,Heavy-Chain Immunoglobulins,Ig Heavy Chains,Immunoglobulin Heavy Chain,Immunoglobulin Heavy Chain Subgroup VH-I,Immunoglobulin Heavy Chain Subgroup VH-III,Heavy Chain Immunoglobulins,Heavy Chain, Immunoglobulin,Heavy Chains, Ig,Heavy Chains, Immunoglobulin,Immunoglobulin Heavy Chain Subgroup VH I,Immunoglobulin Heavy Chain Subgroup VH III,Immunoglobulins, Heavy Chain
D007145 Immunoglobulin kappa-Chains One of the types of light chains of the immunoglobulins with a molecular weight of approximately 22 kDa. Ig kappa Chains,Immunoglobulins, kappa-Chain,kappa-Immunoglobulin Light Chains,Immunoglobulin kappa-Chain,kappa-Chain Immunoglobulins,kappa-Immunoglobulin Light Chain,kappa-Immunoglobulin Subgroup VK-12,kappa-Immunoglobulin Subgroup VK-21,Chains, Ig kappa,Immunoglobulin kappa Chain,Immunoglobulin kappa Chains,Immunoglobulins, kappa Chain,Light Chain, kappa-Immunoglobulin,Light Chains, kappa-Immunoglobulin,kappa Chain Immunoglobulins,kappa Chains, Ig,kappa Immunoglobulin Light Chain,kappa Immunoglobulin Light Chains,kappa Immunoglobulin Subgroup VK 12,kappa Immunoglobulin Subgroup VK 21,kappa-Chain, Immunoglobulin,kappa-Chains, Immunoglobulin
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012984 Software Sequential operating programs and data which instruct the functioning of a digital computer. Computer Programs,Computer Software,Open Source Software,Software Engineering,Software Tools,Computer Applications Software,Computer Programs and Programming,Computer Software Applications,Application, Computer Software,Applications Software, Computer,Applications Softwares, Computer,Applications, Computer Software,Computer Applications Softwares,Computer Program,Computer Software Application,Engineering, Software,Open Source Softwares,Program, Computer,Programs, Computer,Software Application, Computer,Software Applications, Computer,Software Tool,Software, Computer,Software, Computer Applications,Software, Open Source,Softwares, Computer Applications,Softwares, Open Source,Source Software, Open,Source Softwares, Open,Tool, Software,Tools, Software
D015202 Protein Engineering Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes. Genetic Engineering of Proteins,Genetic Engineering, Protein,Proteins, Genetic Engineering,Engineering, Protein,Engineering, Protein Genetic,Protein Genetic Engineering

Related Publications

K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
Bringing the Heavy Chain to Light: Creating a Symmetric, Bivalent IgG-Like Bispecific.
November 2020, Antibodies (Basel, Switzerland),
K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
Production and characterization of murine monoclonal antibodies specific for baboon IgG heavy and light chain epitopes.
September 1994, Journal of medical primatology,
K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.
February 2014, Nature biotechnology,
K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients.
January 2017, mAbs,
K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design.
September 2017, The Biochemical journal,
K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells.
October 2019, mAbs,
K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies.
January 2022, mAbs,
K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
Discrete renal deposition of IgM heavy chain and κ light chain in Waldenström macroglobulinemia (IgM-κ).
October 2012, Clinical kidney journal,
K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
A Transgenic Heavy Chain IgG Mouse Platform as a Source of High Affinity Fully Human Single-Domain Antibodies for Therapeutic Applications.
January 2022, Methods in molecular biology (Clifton, N.J.),
K J Froning, and A Leaver-Fay, and X Wu, and S Phan, and L Gao, and F Huang, and A Pustilnik, and M Bacica, and K Houlihan, and Q Chai, and J R Fitchett, and J Hendle, and B Kuhlman, and S J Demarest
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
March 2022, Signal transduction and targeted therapy,
Copied contents to your clipboard!